Overview

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these subjects.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Islet Amyloid Polypeptide
Pramlintide